Eli Lilly and Company reports new data point to significant itch relief for pediatric eczema Traders Union Source link
Deucravacitinib Shows Significant Efficacy and Safety in Phase 3b/4 Trial for Moderate to Severe Scalp Psoriasis Dermatology Times Source link
– Statistically significant improvements in IGA (Investigator Global Assessment) and EASI ( Eczema Area and Severity Index) scores – Fast itch reduction by day 4 and sustained itch reduction – Body Surface Area (BSA) reduction of at least 50 percent – Significant improvement in Skin Infection Rating Scale (SIRS) ANNAPOLIS, Md. , July 10, 2023 […]
Dupixent® (dupilumab) Late-Breaking Data at AAD Show Significant … GlobeNewswire Source link